MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer

Seminars in Cell and Developmental Biology

Volumn 50, Issue , 2016, Pages 133-142

  Donzelli, Sara ^a   Cioce, Mario ^a   Muti, Paola ^b   Strano, Sabrina ^a,b   Yarden, Yosef ^c   Blandino, Giovanni ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer; Chemoresistance; Epidermal growth factor receptor (EGFR); Invasion; MicroRNA; Network; Receptor tyrosine kinase (RTK); Signalling; Tyrosine kinase inhibitor (TKI)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 145; MICRORNA 15B; PROTEIN TYROSINE KINASE; UNTRANSLATED RNA;

CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENICITY; CELL HETEROGENEITY; CELL SUBPOPULATION; CELL SURVIVAL; CELLULAR STRESS SIGNAL; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NEOPLASM; NONHUMAN; ONCOGENE; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; RNA STRUCTURE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGICAL STRESS;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84959360257     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.12.020     Document Type: Review

References (125)

1. Carninci P., Hayashizaki Y. Noncoding rna transcription beyond annotated genes. Curr. Opin. Genet. Dev. 2007, 17:139-144.
2. Carninci P. Non-coding rna transcription: turning on neighbours. Nat. Cell Biol. 2008, 10:1023-1024.
3. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
4. Dennis C. The brave new world of rna. Nature 2002, 418:122-124.
5. Mattick J.S. The functional genomics of noncoding rna. Science 2005, 309:1527-1528.
6. Carninci P. Molecular biology: the long and short of rnas. Nature 2009, 457:974-975.
7. Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., Oyama R., Ravasi T., Lenhard B., Wells C., et al. The transcriptional landscape of the mammalian genome. Science 2005, 309:1559-1563.
8. Mattick J.S., Makunin I.V. Non-coding rna. Hum. Mol. Genet. 2006, 15:R17-R29. Spec No 1.
9. Paschoal A.R., Maracaja-Coutinho V., Setubal J.C., Simoes Z.L., Verjovski-Almeida S., Durham A.M. Non-coding transcription characterization and annotation: a guide and web resource for non-coding rna databases. RNA Biol. 2012, 9:274-282.
10. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding rnas: insights into functions. Nat. Rev. Genet. 2009, 10:155-159.
11. Geisler S., Coller J. RNA in unexpected places: long non-coding rna functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 2013, 14:699-712.
12. Brockdorff N. Noncoding rna and polycomb recruitment. RNA 2013, 19:429-442.
13. Gong C., Maquat L.E. Lncrnas transactivate stau1-mediated mrna decay by duplexing with 3' utrs via alu elements. Nature 2011, 470:284-288.
14. Hannon G.J. Rna interference. Nature 2002, 418:244-251.
15. Mello C.C. Return to the rnai world: rethinking gene expression and evolution (nobel lecture). Angew. Chem. Int. Ed. Engl. 2007, 46:6985-6994.
16. Mello C.C., Conte D. Revealing the world of rna interference. Nature 2004, 431:338-342.
17. Brennecke J., Aravin A.A., Stark A., Dus M., Kellis M., Sachidanandam R., Hannon G.J. Discrete small rna-generating loci as master regulators of transposon activity in Drosophila. Cell 2007, 128:1089-1103.
18. Czech B., Malone C.D., Zhou R., Stark A., Schlingeheyde C., Dus M., Perrimon N., Kellis M., Wohlschlegel J.A., Sachidanandam R., et al. An endogenous small interfering rna pathway in Drosophila. Nature 2008, 453:798-802.
19. Girard A., Sachidanandam R., Hannon G.J., Carmell M.A. A germline-specific class of small rnas binds mammalian piwi proteins. Nature 2006, 442:199-202.
20. Grimson A., Srivastava M., Fahey B., Woodcroft B.J., Chiang H.R., King N., Degnan B.M., Rokhsar D.S., Bartel D.P. Early origins and evolution of micrornas and piwi-interacting rnas in animals. Nature 2008, 455:1193-1197.
21. Malone C.D., Brennecke J., Dus M., Stark A., McCombie W.R., Sachidanandam R., Hannon G.J. Specialized pirna pathways act in germline and somatic tissues of the drosophila ovary. Cell 2009, 137:522-535.
22. Sabin L.R., Zheng Q., Thekkat P., Yang J., Hannon G.J., Gregory B.D., Tudor M., Cherry S. Dicer-2 processes diverse viral rna species. PLoS One 2013, 8:e55458.
23. Carthew R.W., Sontheimer E.J. Origins and mechanisms of mirnas and sirnas. Cell 2009, 136:642-655.
24. Bartel D.P. Micrornas: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
25. Agarwal V., Bell G.W., Nam J.W., Bartel D.P. Predicting effective microrna target sites in mammalian mrnas. Elife 2015, 4.
26. Kozomara A., Griffiths-Jones S. Mirbase: annotating high confidence micrornas using deep sequencing data. Nucleic Acids Res. 2014, 42:D68-D73.
27. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microrna targets. Cell 2003, 115:787-798.
28. Friedman J.M., Jones P.A. Micrornas critical mediators of differentiation, development and disease. Swiss Med. Wkly. 2009, 139:466-472.
29. Bushati N., Cohen S.M. Microrna functions. Annu. Rev. Cell Dev. Biol. 2007, 23:175-205.
30. Croce C.M. Causes and consequences of microrna dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
31. Ghorai A., Ghosh U. Mirna gene counts in chromosomes vary widely in a species and biogenesis of mirna largely depends on transcription or post-transcriptional processing of coding genes. Front. Genet. 2014, 5(100).
32. Baskerville S., Bartel D.P. Microarray profiling of micrornas reveals frequent coexpression with neighboring mirnas and host genes. RNA 2005, 11:241-247.
33. Bentwich I. Prediction and validation of micrornas and their targets. FEBS Lett. 2005, 579:5904-5910.
34. Cai X., Hagedorn C.H., Cullen B.R. Human micrornas are processed from capped, polyadenylated transcripts that can also function as mrnas. RNA 2004, 10:1957-1966.
35. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., Kim V.N. Microrna genes are transcribed by rna polymerase II. EMBO J. 2004, 23:4051-4060.
36. Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., Shiekhattar R. The microprocessor complex mediates the genesis of micrornas. Nature 2004, 432:235-240.
37. Bohnsack M.T., Czaplinski K., Gorlich D. Exportin 5 is a rangtp-dependent dsrna-binding protein that mediates nuclear export of pre-mirnas. RNA 2004, 10:185-191.
38. Yi R., Doehle B.P., Qin Y., Macara I.G., Cullen B.R. Overexpression of exportin 5 enhances rna interference mediated by short hairpin rnas and micrornas. RNA 2005, 11:220-226.
39. Zhang X., Henderson I.R., Lu C., Green P.J., Jacobsen S.E. Role of rna polymerase iv in plant small rna metabolism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4536-4541.
40. Nasser M.W., Datta J., Nuovo G., Kutay H., Motiwala T., Majumder S., Wang B., Suster S., Jacob S.T., Ghoshal K. Down-regulation of micro-rna-1 (mir-1) in lung cancer: suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by mir-1. J. Biol. Chem. 2008, 283:33394-33405.
41. Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R. Human risc couples microrna biogenesis and posttranscriptional gene silencing. Cell 2005, 123:631-640.
42. Lee Y., Hur I., Park S.Y., Kim Y.K., Suh M.R., Kim V.N. The role of pact in the rna silencing pathway. EMBO J. 2006, 25:522-532.
43. Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., Korc M., Kleeff J., Buchler M.W. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48:558-564.
44. MacRae I.J., Ma E., Zhou M., Robinson C.V., Doudna J.A. In vitro reconstitution of the human risc-loading complex. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:512-517.
45. Kim S.K., Nam J.W., Rhee J.K., Lee W.J., Zhang B.T. Mitarget microrna target gene prediction using a support vector machine. BMC Bioinf. 2006, 7:411.
46. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mrna translation and stability by micrornas. Annu. Rev. Biochem. 2010, 79:351-379.
47. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by micrornas: are the answers in sight. Nat. Rev. Genet. 2008, 9:102-114.
48. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. Microrna targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
49. Kalman S., Garbett K.A., Vereczkei A., Shelton R.C., Korade Z., Mirnics K. Metabolic stress-induced microrna and mrna expression profiles of human fibroblasts. Exp. Cell. Res. 2014, 320:343-353.
50. Blandino G., Valerio M., Cioce M., Mori F., Casadei L., Pulito C., Sacconi A., Biagioni F., Cortese G., Galanti S., et al. Metformin elicits anticancer effects through the sequential modulation of dicer and c-myc. Nat. Commun. 2012, 3:865.
51. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., et al. P53-mediated activation of mirna34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
52. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., et al. Transactivation of mir-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
53. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., et al. A microrna component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
54. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of mir-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26:731-743.
55. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., Hermeking H. Differential regulation of micrornas by p53 revealed by massively parallel sequencing: mir-34a is a p53 target that induces apoptosis and g1-arrest. Cell Cycle 2007, 6:1586-1593.
56. Benassi B., Flavin R., Marchionni L., Zanata S., Pan Y., Chowdhury D., Marani M., Strano S., Muti P., Blandino G., et al. Myc is activated by USP2a-mediated modulation of micrornas in prostate cancer. Cancer Discov. 2012, 2:236-247.
57. Masciarelli S., Fontemaggi G., Di Agostino S., Donzelli S., Carcarino E., Strano S., Blandino G. Gain-of-function mutant p53 downregulates mir-223 contributing to chemoresistance of cultured tumor cells. Oncogene 2014, 33:1601-1608.
58. Donzelli S., Fontemaggi G., Fazi F., Di Agostino S., Padula F., Biagioni F., Muti P., Strano S., Blandino G. Microrna-128-2 targets the transcriptional repressor e2f5 enhancing mutant p53 gain of function. Cell Death Differ. 2012, 19:1038-1048.
59. Li Z.F., Liang Y.M., Lau P.N., Shen W., Wang D.K., Cheung W.T., Xue C.J., Poon L.M., Lam Y.W. Dynamic localisation of mature micrornas in human nucleoli is influenced by exogenous genetic materials. PLoS One 2013, 8:e70869.
60. Upton J.P., Wang L., Han D., Wang E.S., Huskey N.E., Lim L., Truitt M., McManus M.T., Ruggero D., Goga A., et al. Ire1alpha cleaves select micrornas during er stress to derepress translation of proapoptotic caspase-2. Science 2012, 338:818-822.
61. Leung A.K., Calabrese J.M., Sharp P.A. Quantitative analysis of argonaute protein reveals microrna-dependent localization to stress granules. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18125-18130.
62. Anderson E., Boese Q., Khvorova A., Karpilow J. Identifying sirna-induced off-targets by microarray analysis. Methods Mol. Biol. 2008, 442:45-63.
63. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., et al. Frequent deletions and down-regulation of micro- rna genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15524-15529.
64. Dong J.T. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2001, 20:173-193.
65. Di Leva G., Croce C.M. Roles of small rnas in tumor formation. Trends Mol. Med. 2010, 16:257-267.
66. Mendell J.T., Olson E.N. Micrornas in stress signaling and human disease. Cell 2012, 148:1172-1187.
67. Bailey S.G., Sanchez-Elsner T., Stephanou A., Cragg M.S., Townsend P.A. Regulating the genome surveillance system: mirnas and the p53 super family. Apoptosis 2010, 15:541-552.
68. Calin G.A., Croce C.M. Microrna signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
69. Esquela-Kerscher A., Slack F.J. Oncomirs - micrornas with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
70. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., et al. Microrna expression profiles classify human cancers. Nature 2005, 435:834-838.
71. Kumar M.S., Lu J., Mercer K.L., Golub T.R., Jacks T. Impaired microrna processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
72. Avraham R., Sas-Chen A., Manor O., Steinfeld I., Shalgi R., Tarcic G., Bossel N., Zeisel A., Amit I., Zwang Y., et al. Egf decreases the abundance of micrornas that restrain oncogenic transcription factors. Sci. Signal. 2010, 3:ra43.
73. Lopez-Serra P., Esteller M. DNA methylation-associated silencing of tumor-suppressor micrornas in cancer. Oncogene 2012, 31:1609-1622.
74. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., Benjamin H., Shabes N., Tabak S., Levy A., et al. Micrornas accurately identify cancer tissue origin. Nat. Biotechnol. 2008, 26:462-469.
75. F. Ganci, A. Sacconi, V. Manciocco, I. Sperduti, P. Battaglia, R. Covello, P. Muti, S. Strano, G. Spriano, G. Fontemaggi, et al. Microrna expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head Neck, 2014.
76. Sacconi A., Biagioni F., Canu V., Mori F., Di Benedetto A., Lorenzon L., Ercolani C., Di Agostino S., Cambria A.M., Germoni S., et al. Mir-204 targets bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012, 3:e423.
77. Biagioni F., Bossel Ben-Moshe N., Fontemaggi G., Canu V., Mori F., Antoniani B., Di Benedetto A., Santoro R., Germoni S., De Angelis F., et al. Mir-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol. Med. 2012, 4:1214-1229.
78. Mori F., Sacconi A., Canu V., Ganci F., Novello M., Anelli V., Covello R., Ferraresi V., Muti P., Biagini R., et al. Mir-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget 2015, 6:13946-13961.
79. Ganci F., Sacconi A., Bossel Ben-Moshe N., Manciocco V., Sperduti I., Strigari L., Covello R., Benevolo M., Pescarmona E., Domany E., et al. Expression of tp53 mutation-associated micrornas predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann. Oncol. 2013, 24:3082-3088.
80. Muti P., Sacconi A., Hossain A., Donzelli S., Ben Moshe N.B., Ganci F., Sieri S., Krogh V., Berrino F., Biagioni F., et al. Downregulation of micrornas 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: the ordet prospective study. Cancer Epidemiol. Biomark. Prev. 2014, 23:2471-2481.
81. Hu Y., Yu C.Y., Wang J.L., Guan J., Chen H.Y., Fang J.Y. Microrna sequence polymorphisms and the risk of different types of cancer. Sci. Rep. 2014, 4(3648).
82. Calin G.A., Croce C.M. Chronic lymphocytic leukemia: interplay between noncoding rnas and protein-coding genes. Blood 2009, 114:4761-4770.
83. Gomez G.G., Wykosky J., Zanca C., Furnari F.B., Cavenee W.K. Therapeutic resistance in cancer: microrna regulation of egfr signaling networks. Cancer Biol. Med. 2013, 10:192-205.
84. Han F., He J., Li F., Yang J., Wei J., Cho W.C., Liu X. Emerging roles of micrornas in egfr-targeted therapies for lung cancer. Biomed Res. Int. 2015, 2015(672759).
85. Kedmi M., Sas-Chen A., Yarden Y. Micrornas and growth factors: an alliance propelling tumor progression. J. Clin. Med. 2015, 4:1578-1599.
86. Zhang Y., Kim J., Mueller A.C., Dey B., Yang Y., Lee D.H., Hachmann J., Finderle S., Park D.M., Christensen J., et al. Multiple receptor tyrosine kinases converge on microrna-134 to control kras, stat5b, and glioblastoma. Cell Death Differ. 2014, 21:720-734.
87. Castoldi R., Ecker V., Wiehle L., Majety M., Busl-Schuller R., Asmussen M., Nopora A., Jucknischke U., Osl F., Kobold S., et al. A novel bispecific egfr/met antibody blocks tumor-promoting phenotypic effects induced by resistance to egfr inhibition and has potent antitumor activity. Oncogene 2013, 32:5593-5601.
88. Caescu C.I., Guo X., Tesfa L., Bhagat T.D., Verma A., Zheng D., Stanley E.R. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microrna-21. Blood 2015, 125:e1-13.
89. Sampaio N.G., Yu W., Cox D., Wyckoff J., Condeelis J., Stanley E.R., Pixley F.J. Phosphorylation of csf-1r y721 mediates its association with pi3k to regulate macrophage motility and enhancement of tumor cell invasion. J. Cell Sci. 2011, 124:2021-2031.
90. Mouchemore K.A., Sampaio N.G., Murrey M.W., Stanley E.R., Lannutti B.J., Pixley F.J. Specific inhibition of pi3k p110delta inhibits csf-1-induced macrophage spreading and invasive capacity. FEBS J. 2013, 280:5228-5236.
91. Xiong B., Cheng Y., Ma L., Zhang C. Mir-21 regulates biological behavior through the pten/pi-3 k/akt signaling pathway in human colorectal cancer cells. Int. J. Oncol. 2013, 42:219-228.
92. Dong Y., Yu J., Ng S.S. Microrna dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag. Res. 2014, 6:405-422.
93. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. Microrna-21 regulates expression of the pten tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
94. Qin X., Yan L., Zhao X., Li C., Fu Y. Microrna-21 overexpression contributes to cell proliferation by targeting pten in endometrioid endometrial cancer. Oncol. Lett. 2012, 4:1290-1296.
95. Bai J., Zhu X., Ma J., Wang W. Mir-205 regulates a549 cells proliferation by targeting pten. Int. J. Clin. Exp. Pathol. 2015, 8:1175-1183.
96. Shen J., Xia W., Khotskaya Y.B., Huo L., Nakanishi K., Lim S.O., Du Y., Wang Y., Chang W.C., Chen C.H., et al. Egfr modulates microrna maturation in response to hypoxia through phosphorylation of ago2. Nature 2013, 497:383-387.
97. Chou Y.T., Lin H.H., Lien Y.C., Wang Y.H., Hong C.F., Kao Y.R., Lin S.C., Chang Y.C., Lin S.Y., Chen S.J., et al. Egfr promotes lung tumorigenesis by activating mir-7 through a ras/erk/myc pathway that targets the ets2 transcriptional repressor erf. Cancer Res. 2010, 70:8822-8831.
98. Kedmi M., Ben-Chetrit N., Korner C., Mancini M., Ben-Moshe N.B., Lauriola M., Lavi S., Biagioni F., Carvalho S., Cohen-Dvashi H., et al. Egf induces micrornas that target suppressors of cell migration: mir-15b targets mtss1 in breast cancer. Sci. Signal. 2015, 8:ra29.
99. Guo Y.H., Zhang C., Shi J., Xu M.H., Liu F., Yuan H.H., Wang J.Y., Jiang B., Gao F.H. Abnormal activation of the egfr signaling pathway mediates the downregulation of mir145 through the erk1/2 in non-small cell lung cancer. Oncol. Rep. 2014, 31:1940-1946.
100. Cho W.C., Chow A.S., Au J.S. Mir-145 inhibits cell proliferation of human lung adenocarcinoma by targeting egfr and nudt1. RNA Biol. 2011, 8:125-131.
101. S. Donzelli, F. Mori, T. Bellissimo, A. Sacconi, B. Casini, T. Frixa, G. Roscilli, L. Aurisicchio, F. Facciolo, A. Pompili, et al. Epigenetic silencing of mir-145-5p contributes to brain metastasis. oncotarget (in press).
102. Zhang K.L., Han L., Chen L.Y., Shi Z.D., Yang M., Ren Y., Chen L.C., Zhang J.X., Pu P.Y., Kang C.S. Blockage of a mir-21/egfr regulatory feedback loop augments anti-egfr therapy in glioblastomas. Cancer Lett. 2014, 342:139-149.
103. Cappuzzo F., Sacconi A., Landi L., Ludovini V., Biagioni F., D'Incecco A., Capodanno A., Salvini J., Corgna E., Cupini S., et al. Microrna signature in metastatic colorectal cancer patients treated with anti-egfr monoclonal antibodies. Clin. Colorectal Cancer 2014, 13:37-45. e34.
104. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. 2nd. Functional selectivity of egf family peptide growth factors: implications for cancer. Pharmacol. Ther. 2009, 122:1-8.
105. Macdonald-Obermann J.L., Pike L.J. Different epidermal growth factor (egf) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. J. Biol. Chem. 2014, 289:26178-26188.
106. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., Ho B.C., Chang G.C., Shih J.Y., Yu S.L., et al. Pretreatment epidermal growth factor receptor (egfr) t790 m mutation predicts shorter egfr tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:433-440.
107. Remon J., Moran T., Majem M., Reguart N., Dalmau E., Marquez-Medina D., Lianes P. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in egfr-mutant non-small cell lung cancer: a new era begins. Cancer Treat. Rev. 2014, 40:93-101.
108. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
109. Pao W., Miller V.A., Kris M.G. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (iressa) in non-small cell lung cancer (nsclc). Semin. Cancer Biol. 2004, 14:33-40.
110. Seike M., Goto A., Okano T., Bowman E.D., Schetter A.J., Horikawa I., Mathe E.A., Jen J., Yang P., Sugimura H., et al. Mir-21 is an egfr-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12085-12090.
111. Bjaanaes M.M., Halvorsen A.R., Solberg S., Jorgensen L., Dragani T.A., Galvan A., Colombo F., Anderlini M., Pastorino U., Kure E., et al. Unique microrna-profiles in egfr-mutated lung adenocarcinomas. Int. J. Cancer 2014, 135:1812-1821.
112. Chan L.W., Wang F.F., Cho W.C. Genomic sequence analysis of egfr regulation by micrornas in lung cancer. Curr. Top. Med. Chem. 2012, 12:920-926.
113. Dacic S., Kelly L., Shuai Y., Nikiforova M.N. Mirna expression profiling of lung adenocarcinomas: correlation with mutational status. Mod. Pathol. 2010, 23:1577-1582.
114. Piotrowska Z., Niederst M.J., Karlovich C.A., Wakelee H.A., Neal J.W., Mino-Kenudson M., Fulton L., Hata A.N., Lockerman E.L., Kalsy A., et al. Heterogeneity underlies the emergence of egfrt790 wild-type clones following treatment of t790m-positive cancers with a third-generation egfr inhibitor. Cancer Discov. 2015, 5:713-722.
115. Inda M.M., Bonavia R., Mukasa A., Narita Y., Sah D.W., Vandenberg S., Brennan C., Johns T.G., Bachoo R., Hadwiger P., et al. Tumor heterogeneity is an active process maintained by a mutant egfr-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24:1731-1745.
116. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X., Levine A.D., Rho J.K., et al. Activation of the axl kinase causes resistance to egfr-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.
117. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., et al. Met amplification occurs with or without t790m mutations in egfr mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20932-20937.
118. Yano S. Studies for mechanism of drug resistance to egfr-tki. Gan To Kagaku Ryoho 2010, 37:1463-1466.
119. Benedettini E., Sholl L.M., Peyton M., Reilly J., Ware C., Davis L., Vena N., Bailey D., Yeap B.Y., Fiorentino M., et al. Met activation in non-small cell lung cancer is associated with de novo resistance to egfr inhibitors and the development of brain metastasis. Am. J. Pathol. 2010, 177:415-423.
120. Garofalo M., Romano G., Di Leva G., Nuovo G., Jeon Y.J., Ngankeu A., Sun J., Lovat F., Alder H., Condorelli G., et al. Egfr and met receptor tyrosine kinase-altered microrna expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 2012, 18:74-82.
121. Acunzo M., Romano G., Palmieri D., Lagana A., Garofalo M., Balatti V., Drusco A., Chiariello M., Nana-Sinkam P., Croce C.M. Cross-talk between met and egfr in non-small cell lung cancer involves mir-27a and sprouty2. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8573-8578.
122. Wang Y., Xia H., Zhuang Z., Miao L., Chen X., Cai H. Axl-altered micrornas regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis. 2014, 5:e1227.
123. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., Todd D.G., Valerie K., Kavanagh B.D., Contessa J.N., Rorrer W.K., Chen P.B. Radiation-induced proliferation of the human a431 squamous carcinoma cells is dependent on egfr tyrosine phosphorylation. Oncogene 1997, 15:1191-1197.
124. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., Amorino G., Lin P.S. Erbb receptor tyrosine kinases and cellular radiation responses. Oncogene 2003, 22:5855-5865.
125. Cheng N., Li X., Zhao C., Ren S., Chen X., Cai W., Zhao M., Zhang Y., Li J., Wang Q., et al. Microarray expression profile of long non-coding rnas in egfr-tkis resistance of human non-small cell lung cancer. Oncol. Rep. 2015, 33:833-839.